A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 31 Mar 2017 Planned End Date changed from 1 Feb 2019 to 1 Sep 2019.
- 31 Mar 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.
- 31 Mar 2017 Status changed from active, no longer recruiting to recruiting.